

3.2.1 Extramural funding for Research (Grants sponsored by the non-Govt. sources such as industry, corporate houses, international bodies for research projects) endowments, Chairs in the University during the year(INR in Lakhs)

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| A phase II randomized study to evaluate the efficacy of short-course RR CVP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma | Dr. Manju Sengar | TRAC and Unrestricted Educational grants from Non-Govt. companies AND DONORS | Non-Govt. | Medical and Health Sciences | 8/17/2020 | 139.65 | 2 Years | TMC |
| A prospective, multicentre, post-marketing phase IV study to assess the safety and efficacy of Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) | Dr. Vikas Ostwal | Eisai Non-Govt. ceuticals, India Pvt. Ltd. 6th Floor, A Wing, Marwah Center, Krishanlal Marwah Marg, Andheri East, Mumbai 400072. Maharashtra, INDIA. Phon | Non-Govt. | Medical and Health Sciences | 1/12/2021 | 37.60 | 2 Years 6 Months | TMC |
| COVID-19 with Hematological Cancers Registry of India (CHCRI) | Dr. Lingaraj Nayak | Hematology Cancer Consortium (HCC) | Non-Govt. | Medical and Health Sciences | 3/23/2021 | 1.08 | 1 Years 6 Months | TMC |
| Evaluation of the effect of foot bathing on peripheral neuropathy in patients receiving oxaliplatin containing chemotherapy for GI cancer at Tata Memorial Hospital | Mrs. Anita D Souza | IASCC | Non-Govt. | Medical and Health Sciences | 2021 | 2.41 | 3 Years | TMC |
| Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial | Dr. Jigeeshu Divatia | The George Institute for Global Health Plot No. 57, Second Floor, Corporation Bank Building Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telanga | Non-Govt. | Medical and Health Sciences | 10/5/2020 | 6 | 2 Years | TMC |
| Indian Pulmonary Embolism Registry (IndiPER) | Dr. Sohan Solanki | ETERNAL HOSPITAL JAIPUR | Non-Govt. | Medical and Health Sciences | 9/3/2020 | 1.50E-01 | 2 Years | TMC |
| Investigating the role of RUNX1 and ID proteins for targeting the Cancer Stem Cell Population in primary and relapsed Epithelial Ovarian Cancer | PI: Dr Pritha Ray. COI: Dr Bharat Rekhi | Lady Tata Memorial Trust | Non-Govt. | Medical and Health Sciences | 2021 | 49.99 | 3 years | TMC |
| Molecular genetic analysis of Leukoplakia to identify high risk lesion | Manoj Mahimkar/ Neha Mittal | Terry fox foundation | Non-Govt. | Medical and Health Sciences | 2020 | 167.38 | 5 yrs | TMC |
| Observation or upfront cranial RT in oncogene driver mutated NSCLC with asymptomatic brain metastases: A phase III Randomized Controlled Trial | Dr. Anil Tibdewal | EM- NEUROONCOLOGY RESEARCH FUND | Non-Govt. | Medical and Health Sciences | 7/23/2020 | 85.6 | 6 Years | TMC |
| PIK3CA Registry- A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer. | Dr. Sudeep Gupta | NOVARTIS HEALTHCARE PRIVATE LIMITED | Non-Govt. | Medical and Health Sciences | 11/11/2020 | 9.76 | 2 Years | TMC |
| Project I - Early Detection of Common Cancers among Women in India | Dr. Rajendra Badwe | National Institute Of Health, USA | Non-Govt. | Medical and Health Sciences | 1996 | 1061 | 26 Years | TMC |
| Protocol No. - ACE-ID-201 (D822FC00001) : A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 | Dr. Anant Ramaswamy | Astrazenca Non-Govt. India Ltd | Non-Govt. | Medical and Health Sciences | 7/20/2020 | 74.55 | 6 Months | TMC |

Compilation of data as received from Dean - Academic of the various CIs/OCC of HBTMS
 प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा नॅशनल इंस्टीट्यूट
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्र भवन, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Protocol No. - D9106C00001 : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) | Dr. C. S. Pramesh | Astra Zeneca AB | Non-Govt. | Medical and Health Sciences | 1/8/2021 | 66.47 | 7 Years | TMC |
| Role of water pollution in development of esophageal cancer: a case-control stratified by high and low risk regions. | Dr. Rajesh Dikshit | Department of Health Research | Non-Govt. | Medical and Health Sciences | 8/6/2020 | 65.8 | 2 Years | TMC |
| Seroprevalence of COVID-19 in slum and non slum areas of Mumbai | Dr. Rajesh Dikshit | i-spirit | Non-Govt. | Medical and Health Sciences | 7/7/2020 | 201.01 | 3 Months | TMC |
| TMH IRIS: Proposal for participation of TMH ICU in the Indian Registry of Intensive care (IRIS) | Dr. Atul Kulkarni | Chennai Critical Care Consultants Group | Non-Govt. | Medical and Health Sciences | 3/15/2021 | 2.61 | 1 Years | TMC |
| A Double Blind, Placebo- Controlled, Randomized Phase III Study of IPATASERTIB in combination with Paclitaxel As a treatment for patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple Negative Breast cancer or Hormone Receptor -Positive, HER2 -Negative Breast Cancer | Dr. Sudeep Gupta | F. Hoffmann-La Roche Ltd (hereafter referred to as Roche) globally and in India through its affiliate, Roche Products (India) Pvt. Ltd. (RPIPL) | Non-Govt. | Medical and Health Sciences | 7/1/2019 | 327.74 | 5 Years | TMC |
| A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients with Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer who have received Prior Treatment with Trastuzumab and a Taxane | Dr. Sudeep Gupta | ROCHE PRODUCTS PVT LTD | Non-Govt. | Medical and Health Sciences | 2/29/2016 | 84.68 | 6 Years | TMC |
| A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | Dr. Vijay Patil | Novartis Healthcare Pvt. Ltd. | Non-Govt. | Medical and Health Sciences | 4/30/2019 | 89.05 | 7 Years | TMC |
| A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck | Dr. Kumar Prabhash | Roche Products (India) | Non-Govt. | Medical and Health Sciences | 5/7/2018 | 141.74 | 7 Years | TMC |
| A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) | Dr. Vikas Ostwal | AstraZeneca Non-Govt. India Ltd. | Non-Govt. | Medical and Health Sciences | 11/19/2019 | 57.70 | 4 Years | TMC |
| A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC) | Dr. Vikas Ostwal | Bayer AG, D-51368 Leverkusen, Germany | Non-Govt. | Medical and Health Sciences | 7/9/2018 | 87.49 | 4 Years | TMC |

प्रो. पी. डी. नाईक / Prof. P. D. Naik
डीन, होमी भाभा राष्ट्रीय संस्थान

Dr. Hemli Bhatia National Institute
प्रशिक्षण विद्यालय भवन, आप्तकर्मिनीनगर, मुंबई - 400 094
Training School Complex, Anushaktinagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic of the various CIs/OCCs of TMC

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer. | Dr. Shalaka Joshi | ALKEM LABORATORIES LTD | Non-Govt. | Medical and Health Sciences | 11/13/2017 | 57.36 | 4 Years 6 Months | TMC |
| A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study) | Dr. Sudeep Gupta | AstraZeneca Non-Govt. India Limited | Non-Govt. | Medical and Health Sciences | 10/14/2020 | 147.67 | 3 Years | TMC |
| A Prospective, Single arm, Multi-centre, Post-marketing Study (Phase IV) to evaluate safety and efficacy of Dr. Reddy's Trastuzumab (DRL_TZ) in Patients with HER2-Positive Cancer | Dr. Sudeep Gupta | Dr. Reddy's Laboratories | Non-Govt. | Medical and Health Sciences | 2/24/2020 | 312.17 | 3 Years | TMC |
| A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA). | Dr. Vikas Ostwal | AstraZeneca Non-Govt. India Ltd. | Non-Govt. | Medical and Health Sciences | 5/18/2018 | 40.96 | 4 Years | TMC |
| A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE) | Dr. Seema Gulia | Eli Lilly and Company India Pvt. Ltd. | Non-Govt. | Medical and Health Sciences | 4/9/2018 | 217.30 | 10 Years | TMC |
| A single arm, multicentric, open label, efficacy and safety study of Doceaqualip (Docetaxel Lipid Suspension for Injection of Intas Non-Govt.ceuticals Limited, India) based regimens in metastatic gastric adenocarcinoma patients | Dr. Vikas Ostwal | Intas Non-Govt.ceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India. | Non-Govt. | Medical and Health Sciences | 2/27/2019 | 82.29 | 3 Years 10 Months | TMC |
| An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (CONCORDANCE) | Dr. Kumar Prabhash | AstraZeneca Non-Govt. India Ltd | Non-Govt. | Medical and Health Sciences | 10/26/2018 | 8.58 | 2 Years | TMC |
| An open label, phase I/II study of topical Apaziquone for the treatment of oral leukoplakia | Dr. Pankaj Chaturvedi | Spectrum Oncology Pvt Ltd | Non-Govt. | Medical and Health Sciences | 6/30/2017 | 30.93 | 3 Years 9 Months | TMC |
| An Open-label, Single-arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® (Degarelix) in Androgen Deprivation Therapy in Indian Patients Diagnosed with Advanced Hormone-dependent Prostate Cancer. | Dr. Ganesh Bakshi | FERRING Non-Govt CEUTICAL PVT LTD | Non-Govt. | Medical and Health Sciences | 7/26/2017 | 11.09 | 3 Years 8 Months | TMC |

Compilation of data as received from Dean - Academic of the various Cis/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन (अकादमिक) / Dean (Academic)
 डॉ. होमि भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 अणुशास्त्रीनगर, मुंबई - 400 094
 Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Tumours | Dr. Gouri Pantvaitya | QBiotics Group Limited (QBiotics) | Non-Govt. | Medical and Health Sciences | 12/9/2019 | 70.66 | 4 Years | TMC |
| Multicentre, randomised, double-blind, placebo controlled study of Atezolizumab (anti-PD-L1 antibody) in combination with paclitaxel compared with placebo in combination with paclitaxel for patients with previously untreated, inoperable locally advanced or metastatic Triple Negative Breast Cancer. | Dr. Sudeep Gupta | Roche Products (India) Pvt. Ltd | Non-Govt. | Medical and Health Sciences | 4/18/2018 | 130.33 | 4 Years | TMC |
| "Advancing Cancer-care through CANScripT TM Enabled Personalized Treatment (ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScripT TM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer" | Dr. Shripad Banavali | Mitra Biotech Pvt. Ltd, Bangalore | Non-Govt. | Medical and Health Sciences | 3/22/2018 | 100.00 | 4 Years | TMC |
| A clinical trial to test the number of circulating tumor cells (CTCs) captured by the OncoDiscover Liquid Biopsy Technology in peripheral blood samples of Head and Neck cancer patients. | Dr. Pankaj Chaturvedi | ACTORIUS INNOVATIONS AND RESEARCH PVT LTD. | Non-Govt. | Medical and Health Sciences | 11/17/2017 | 10.16 | 4 Years 6 Months | TMC |
| A New Method for Cervical Cancer Screening in Low- and Middle-Income Countries (LMIC): Training and Technical Validation of Automated Visual Evaluation (AVE) in India | Dr. Rajesh Dikshit | Clinton Health Access Initiative (CHAI), USA | Non-Govt. | Medical and Health Sciences | 10/23/2019 | 891.96 | 2 Years | TMC |
| A Phase 2 randomized controlled trial to evaluate the role of modified C. O. M. B. A. T maintenance regimen in children with high risk medulloblastoma | Dr. Girish Chinnaswamy | Terry Fox | Non-Govt. | Medical and Health Sciences | 10/22/2018 | 58.42 | 4 Years | TMC |
| A Phase II Randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients | Dr. Anil Tibdewal | DHR | Non-Govt. | Medical and Health Sciences | 10/10/2019 | 56.36 | 6 Years | TMC |
| A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study | Dr. Sudeep Gupta | Novartis Healthcare Pvt. Ltd. | Non-Govt. | Medical and Health Sciences | 1/3/2020 | 451.02 | 5 Years | TMC |
| A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease | Dr. Sudeep Gupta | Novartis Healthcare Pvt. Ltd. | Non-Govt. | Medical and Health Sciences | 7/10/2020 | 88.30 | 3 Years | TMC |

Compilation of data as received from Dean-Academic of the various Cis/OCC of HSNL

डॉ. पी. डी. नाईक / Prof. P. D. Naik
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुसंशोधन केंद्र - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer. | Dr. Sabita Jiwnani | NOVARTIS HEALTHCARE | Non-Govt. | Medical and Health Sciences | 7/23/2014 | 39.22 | 7 Years 2 Months | TMC |
| A Phase III randomized clinical trial to study the radiosensitizing effect of Nelfinavir in Advanced Carcinoma of Cervix. (NELCER Trial) | Dr. Supriya Chopra | VARIAN GRANT RESEARCH | Non-Govt. | Medical and Health Sciences | 3/17/2017 | 225.96 | 8 Years | TMC |
| A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer. (MONALEESA-7) | Dr. Jyoti Bajpai | Novartis Healthcare Private Limited | Non-Govt. | Medical and Health Sciences | 12/10/2015 | 179.10 | 7 Years | TMC |
| A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer (TEXT Trial) | Dr. Vani Parmar | IBCSG | Non-Govt. | Medical and Health Sciences | 9/22/2005 | 30.36 | 16 Years | TMC |
| A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer (SOFT Trial) | Dr. Vani Parmar | INTERNATIONAL BREST CANCER STUDY GROUP | Non-Govt. | Medical and Health Sciences | 8/29/2005 | 40.09 | 16 Years | TMC |
| A phase III, double blind, Placebo controlled, randomized trial assessing the effect of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumor. (Add Aspirin Study) | Dr. C. S. Pramesh | TATA TRUST | Non-Govt. | Medical and Health Sciences | 9/2/2016 | 1560.33 | 10 Years | TMC |
| A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent. | Dr. Manju Sengar | Onconova Therapeutics, Inc. | Non-Govt. | Medical and Health Sciences | 11/24/2018 | 10.52 | 3 Years | TMC |
| A phase-3 randomized control trial comparing hydroxyurea and L-asparaginase for cytoreduction in pediatric AML patients presenting with hyperleukocytosis | Dr. Shripad Banavali | SOHN FOUNDATION THROUGH GRAVIS | Non-Govt. | Medical and Health Sciences | 9/27/2018 | 23.59 | 4 Years | TMC |
| A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Cervarix) | Dr. Sharmila Pimple | Serum Institute of India Pvt. Ltd, Hadapsar, Pune (Sponsor) | Non-Govt. | Medical and Health Sciences | 6/28/2018 | 137.25 | 4 Years 9 Months | TMC |

Compilation of data as received from Dean - Academic of the various CIS/OCC of
 प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशास्त्रोत्तार, मुंबई - 400 094
 Training School Complex, Anushastrotar, Mumbai - 400 094
 HBNI.

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIO-EMBRACE-1) | Dr. Supriya Chopra | BIOEMBRACE RESEARCH GROUP | Non-Govt. | Medical and Health Sciences | 2/5/2019 | 23.60 | 3 Years | TMC |
| A pilot study to determine the feasibility of detection of esophageal cancer by sponge cytology technique. | Dr. Sabita Jiwani | Dr. Virginia R. Litle, Boston University, Collamore 7, Suite7380 | Non-Govt. | Medical and Health Sciences | 5/11/2020 | .08 | 2 Years 6 Months | TMC |
| A prospective evaluation of a point of care saliva-based detection test based on soluble CD44 (OncAlert) for the presence of disease in a previously untreated oral cavity and oropharynx squamous cell carcinoma. | Dr. Sudhir Vasudevan Nair | Tata Trusts, Vigilant Biosciences | Non-Govt. | Medical and Health Sciences | 12/13/2018 | 17.06 | 4 Years | TMC |
| A prospective observational study to compare speech and swallowing outcomes in patients undergoing treatment for oral tongue cancers | Dr. Shiva Kumar Thiagarajan | ICON | Non-Govt. | Medical and Health Sciences | 12/16/2019 | 10.00 | 3 Years | TMC |
| A prospective observational study to determine the risk of Hepatitis B viral reactivation in adolescent and adult acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) with Occult Hepatitis B infection (OHB). | Dr. Hasmukh Jain | UNRESTRICTED EDUCATIONAL GRANT | Non-Govt. | Medical and Health Sciences | 10/25/2016 | 2.51 | 8 Years | TMC |
| A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study) | Dr. Sudeep Gupta | Astra Zeneca Non-Govt. India Limited | Non-Govt. | Medical and Health Sciences | 10/14/2020 | 147.67 | 3 Years | TMC |
| A questionnaire survey to assess the quality of informed consent among clinical trial participants | Dr. Vikram Gota | INDOX Coordinating Centre, University of Oxford | Non-Govt. | Life Sciences | 2/5/2009 | 3.09 | 1 Years | TMC |
| A Randomized study comparing Weekly Paclitaxel plus Best Supportive Care to Best Supportive Care Alone in Patients with small cell lung cancer relapsed on two or more lines of chemotherapy (rel. small cell) | Dr. Kumar Prabhash | ICON | Non-Govt. | Medical and Health Sciences | 4/11/2018 | 75.54 | 5 Years | TMC |
| A Randomized Study of the Safety and Efficacy of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer in Patients who Are not Candidates for Curative Surgery and/or Radiation and who Are Receiving Pemetrexed and Carboplatin | Dr. Amit Joshi | CLIANTHA RESEARCH LIMITED | Non-Govt. | Medical and Health Sciences | 6/18/2018 | 36.76 | 2 Years 6 Months | TMC |

Compilation of data as received from Dean - Academic of the various Cis/Occ of
 प्रो. पी. डी. नोईक / Prof. P. D. Nair
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|--------------------------|---------|
| A randomized study to evaluate the effectiveness of Gabapentin on Oral-Mucositis induced pain due to chemo-radio therapy in patients with head and neck cancers. | Dr. Nandini Menon | CADILA | Non-Govt. | Medical and Health Sciences | 3/4/2020 | 21.22 | 3 Years | TMC |
| A randomized trial of concurrent versus sequential Tamoxifen with radiotherapy to assess the extent of pulmonary fibrosis and disease related control and survival in breast cancer patients | Dr. Ashwini Budrukkar | ICMR | Non-Govt. | Medical and Health Sciences | 5/7/2007 | 27.76 | 14 Years 9 Months 2 Days | TMC |
| A randomized trial to evaluate the efficacy and safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients | Dr. Kumar Prabhash | NATCO | Non-Govt. | Medical and Health Sciences | 9/20/2010 | 15.44 | 12 Years | TMC |
| A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer. | Dr. Sushmita Rath | Tanvex Biologics Corp. | Non-Govt. | Medical and Health Sciences | 8/13/2019 | 108.54 | 2 Years | TMC |
| A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib | Dr. Vanita Noronha | SANOFI HEALTHCARE INDIA PRIVATE LIMITED (SHIPL) | Non-Govt. | Medical and Health Sciences | 7/14/2011 | 18.37 | 11 Years | TMC |
| A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes | Dr. Sarbani Ghosh Laskar | IAEA | Non-Govt. | Medical and Health Sciences | 1/24/2017 | 10.53 | 6 Years | TMC |
| A study of lifelong vegetarianism and risk of colorectal cancer in India: an INDOX case control study | Dr. Shaesta Mehta | INDOX Cancer Research Network | Non-Govt. | Medical and Health Sciences | 6/18/2012 | .09 | 7 Years 5 Months 2 Days | TMC |
| A study of Low Dose Bevacizumab with conventional radiotherapy OR Ultra-Low Dose Radiotherapy alone in Diffuse Intrinsic Pontine Glioma. (LoBULaR-DIPG) | Dr. Rahul Krishnatry | Reliance Life Sciences Pvt Ltd + BRAIN TUMOR FUND | Non-Govt. | Medical and Health Sciences | 12/5/2019 | 15.61 | 3 Years | TMC |
| A two arm randomized open label Phase II clinical trial to assess the efficacy of Gemcitabine-cisplatin or Capecitabine and Concurrent chemoradiation in Operated stage II & III GB cancer (GECCOR-GB) | Dr. Anant Ramaswamy | Zydus Non-Govt.ceuticals, Dr. Reddy's Laboratories Limited | Non-Govt. | Medical and Health Sciences | 4/30/2019 | 15.72 | 3 Years | TMC |

Compilation of data as received from Dean - Academic of the various CIs/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विभाग, अणुशक्तिनगर, मुंबई - 400 094
 Training School complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| A two arm randomized open label prospective parallel design superiority Phase II multicentric clinical trial to evaluate the efficacy of a doublet second line chemotherapy versus monotherapy in advanced unresectable or metastatic gall bladder cancer progressing on first line chemotherapy (GB-SFLECT) | Dr. Anant Ramaswamy | TERRY FOX | Non-Govt. | Medical and Health Sciences | 10/3/2017 | 28.45 | 3 Years 6 Months | TMC |
| Adjuvant chemotherapy for operated amPullary AdenoCarcinomas based on Histology and Intensification ; A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI) | Dr. Anant Ramaswamy | Educational Grant - Reliance Life Science | Non-Govt. | Medical and Health Sciences | 4/16/2020 | 11.20 | 7 Years | TMC |
| ALTO-EGF106708- A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer | Dr. Sudeep Gupta | NOVARTIS | Non-Govt. | Medical and Health Sciences | 1/10/2008 | 77.45 | 15 Years | TMC |
| An Epidemiological Study To Evaluate The Prevalence of BRAF, PIK3CA& RAS Mutation In Indian Patients With Colorectal Cancer | Dr. Vikas Ostwal | DR. REDDY'S LAB LTD | Non-Govt. | Medical and Health Sciences | 10/29/2015 | 28.63 | 5 Years | TMC |
| AN OBSERVATIONAL STUDY TO DETERMINE THE ACCURACY OF OXYGEN RESERVE INDEX (ORI) TO PREDICT IMPENDING DESATURATION IN PATIENT'S UNDERGOING PROCEDURES UNDER APNOEA | Dr. Jeson Doctor | Smt KMD Medical Charitable Trust | Non-Govt. | Medical and Health Sciences | 11/25/2020 | 1.30 | 2 Years | TMC |
| An observational study to determine the accuracy of oxygen reserve index (ORI) to predict impending desaturation in patients undergoing procedures under apnoea. | Dr. Jeson Doctor | Smt KMD Medical Charitable Trust | Non-Govt. | Medical and Health Sciences | 11/25/2020 | 1.3 | 2 Years | TMC |
| An open label, prospective three-arm randomized, non-comparative study on efficacy and tolerability of orally disintegrating strip, oral tablets and intravenous administration of Vitamin B12, in post-gastrectomy Indian patients | Dr. Sujay Srinivas | EISAI Non-Govt. CEUTICALS, INTAS | Non-Govt. | Medical and Health Sciences | 2/5/2020 | 38.34 | 6 Years | TMC |
| An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN) | Dr. Kumar Prabhash | BIOCON | Non-Govt. | Medical and Health Sciences | 5/9/2011 | 82.14 | 11 Years | TMC |
| An Open Label, Single Arm, Multicentric, Phase IV study to evaluate the safety and efficacy of Bevacizumab of Intas Non-Govt.ceuticals Limited in approved indications. | Dr. Sudeep Gupta | Intas ceuticals Ltd., 2nd Floor, Chinubhai Centre, Ashram Road, Ahmedabad - 380 009, Gujarat, India. | Non-Govt. | Medical and Health Sciences | 6/21/2018 | 171.05 | 3 Years | TMC |

Compilation of data as received from Dean-Academics of the various ^{पी. डी. नाईक, Prof. P. D. Naik} ~~of~~ ^{डीन, होमी भाभा राष्ट्रीय संस्थान} ~~of~~ ^{Dean, Homi Bhabha National Institute} ~~of~~ ^{प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094} ~~of~~ ^{Training School Complex, Anushaktinagar, Mumbai - 400 094} HBNI.

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|--------------------------|--------------|
| Asia CML Registry (ACR): Web based registry | Dr. Navin Khattry | ASIAN Govt. RESERACH FUND | Non-Govt. | Medical and Health Sciences | 6/27/2011 | 2.77 | 13 Years | TMC |
| Aspirin for Dukes C and high risk Dukes B colorectal cancers an international, multi-centre, double blind, randomized placebo controlled phase III trial | Dr. Shaesta Mehta | INDOX | Non-Govt. | Medical and Health Sciences | 9/15/2011 | 3.00 | 11 Years 1 Months 4 Days | TMC |
| ASSESSMENT OF PLATELET CROSSMATCH RESULTS BY SOLID PHASE RED CELL ADHERENCE ASSAY AMONG PEDIATRIC HEMATO-ONCOLOGY PATIENTS IN A TERTIARY CARE ONCOLOGY CENTRE | Dr. Priti Desai | Immucor India Pvt. Ltd. | Non-Govt. | Medical and Health Sciences | 6/20/2019 | 1.20 | 11 Months | TMC |
| Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India | Dr. Sudeep Gupta | BIOQUEST SOLUTIONS PVT LTD | Non-Govt. | Medical and Health Sciences | 6/27/2014 | 2.87 | 6 Years 7 Months | TMC |
| Cancer Scan Project | Dr. Pratap K. Sahoo | Canostix GmbH, Germany | Non-Govt. | Physical Sciences | 2021 | 22.2 | 3 Years | (From NISER) |
| CAPCYR07568/ METRO- ABC - A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses /Regimens with Metronomic Schedule in Patients with Metastatic Breast Cancer | Dr. Sudeep Gupta | SANOFI SYNTHELABO PVT | Non-Govt. | Medical and Health Sciences | 3/23/2016 | 40.83 | 2 Years | TMC |
| Characterization support involving XRD and HR-SEM-EDS | Dr. Nirav Jamnapara | Uniexcel Agencies and Services Private Limited. | Non-Govt. | Engineering Sciences | 2020 | 3.73 | 12 months | (From IPR) |
| Clinical outcome of common cancers treated with radical intent at HBCH Sangrur- A Retrospective Analysis | Dr. Jai Prakash Agarwal | University of Pennsylvania Philadelphia, US | Non-Govt. | Medical and Health Sciences | 10/17/2019 | 26.40 | 2 Years | TMC |
| Collaborative Action for Control of Cancer and Other Non-Communicable Diseases among Mumbai Police | Dr. Gauravi Mishra | Tata Trusts | Non-Govt. | Medical and Health Sciences | 2/26/2019 | 740.21 | 3 Years | TMC |

Compilation of data as received from Dean - Academic of the various CIS/OCC of

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, आणुशास्त्रनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

HBNI.

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Comparative performance evaluation of Artificial Intelligence (AI) based visual inspection test (AI_VIA) with Primary Health Worker administered VIA (PHW_VIA), HPV DNA test and cervical cytology to detect cervical pre-cancer lesions. | Dr. Sharmila Pimple | Periwinkle Technologies Pvt. Ltd., Pune | Non-Govt. | Medical and Health Sciences | 11/18/2019 | 6.68 | 3 Years | TMC |
| COMPARISON OF TREATMENT ADHERENCE AND TOXICITIES OF HIV POSITIVE PATIENTS VS. HIV NEGATIVE CERVICAL CANCER PATIENTS IN INDIA | Dr. Lavanya Naidu | CRDF Global-ICMR | Non-Govt. | Medical and Health Sciences | 10/30/2019 | 83.03 | 3 Years | TMC |
| CONcurrent versus SEquential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQUENCE) | Dr. Shaiaka Joshi | CSR Fund from Gen. Insu. Co. | Non-Govt. | Medical and Health Sciences | 8/1/2018 | 141.60 | 10 Years | TMC |
| Deep Learning neural network based radiogenomics in predicting clinicopathological outcomes in non-small cell lung cancer | Dr. Abhishek Mahajan | BIRAC-PREDIBLE HEALTH | Non-Govt. | Medical and Health Sciences | 7/26/2018 | 6.74 | 4 Years | TMC |
| Development of a cohort study to identify and evaluate transitions in lifestyle and risk factors in a rural population with a low cancer disease risk at baseline. | Dr. Rajesh Dikshit | World Cancer Research Fund (WCRF), Center for Global Health Research (CGHR), International Agency for Research on cancer (IARC) | Non-Govt. | Medical and Health Sciences | 5/8/2008 | 3000.00 | 13 Years | TMC |
| DHANUSH : Docetaxel as radiosensitizer in Head And Neck cancer patients, Unsuitable for cisplatin based chemoradiation | Dr. Vijay Patil | ICON | Non-Govt. | Medical and Health Sciences | 5/4/2017 | 59.21 | 12 Years | TMC |
| Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children with Acute Lymphoblastic Leukemia: A Pilot Study | Dr. Maya Prasad | SOHN FOUNDATION | Non-Govt. | Medical and Health Sciences | 4/12/2018 | 2.85 | 4 Years | TMC |
| Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation | Dr. Kumar Prabhash | Oncology Care Associates, ICON Trust | Non-Govt. | Medical and Health Sciences | 9/10/2018 | 30.84 | 6 Years | TMC |
| Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial | Dr. Sharmila Pimple | International Agency for Research on Cancer, World Health Organization, Lyon, France | Non-Govt. | Medical and Health Sciences | 10/11/2008 | 252.25 | 18 Years | TMC |

Compilation of data as received from Dean-Academic of the various CIS/OCC of HBN I.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अनुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|---------------------------|---------|
| Effectiveness of a nurse- coordinated home care model in palliative care: a pilot study | Dr. Arunangshu Ghoshal | JEET ASSOCIATION FOR SUPPORT TO CANCER PATIENTS (JASCAP) | Non-Govt. | Medical and Health Sciences | 1/9/2019 | 10.00 | 2 Years 6 Months | TMC |
| Establishment of audit for collating the data of lung cancer patients receiving systemic therapy with palliative intent in India. | Dr. Vanita Noronha | ICON | Non-Govt. | Medical and Health Sciences | 10/8/2012 | 3.60 | 11 Years | TMC |
| Establishment of registry for Epidemiology and end result - analysis in lymphoma (REEA-L) and Establishment of lymphoma tumor tissue repository at the Tata Memorial Hospital (LTTR) | Dr. Navin Khattry | DR. REDDY'S LAB | Non-Govt. | Medical and Health Sciences | 7/7/2010 | 55.00 | 13 Years 9 Months 19 Days | TMC |
| Evaluating The Role Of Genetic Susceptibility For Oropharynx Cancer In Indian Origin Population: a case-control study using the candidate gene approach | Dr. Sharayu Mhatre | ASCO (American Society of Cancer Oncology) | Non-Govt. | Medical and Health Sciences | 3/27/2019 | 14.04 | 3 Years | TMC |
| Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing's sarcoma | Dr. Jyoti Bajpai | Roche Products India Pvt. Ltd | Non-Govt. | Medical and Health Sciences | 11/18/2016 | 62.37 | 7 Years | TMC |
| Genomic Profiling in Thyroid Carcinoma | Dr. Anuradha Chougule | ICON | Non-Govt. | Medical and Health Sciences | 8/17/2015 | 92.44 | 3 Years 6 Months | TMC |
| Grid Oncology: Remaking Cancer Care in India | Dr. C. S. Pramesh | Wellcome Trust | Non-Govt. | Medical and Health Sciences | 6/8/2020 | 30.36 | 3 Years | TMC |
| Health expenditure on breast cancer treatment in women: a study from public sector tertiary cancer centre (EXPERT). | Dr. Tabassum Wadasadawala | WCI-NAG foundation | Non-Govt. | Medical and Health Sciences | 6/7/2019 | 10.00 | 4 Years | TMC |
| Hematological Cancers Consortium: HCC Leukemia Registry | Dr. Manju Sengar | HCC | Non-Govt. | Medical and Health Sciences | 3/22/2019 | 116.84 | 10 Years | TMC |

Compilation of data as received from Dean-Academic of the various Cis/Occ of HBNI.

MDJ

प्रो. पी. डी. नाईक / Prof. P. D. Naik
डीन, होमी भाभा राष्ट्रीय संस्थान

Dean, Homi Bhabha National Institute

प्रशिक्षण विद्यालय भवन, अणुशक्तानगर, मुंबई - 400 094

Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|--------------|
| HEmodynamic Resuscitation and Monitoring in Early Sepsis (HERMES Study) | Dr. Sheila Myatra | ISCCM | Non-Govt. | Medical and Health Sciences | 10/14/2019 | 1.00 | 2 Years 6 Months | TMC |
| Institutment automation for Optoelectronic Characterzation of Tektronix Instruments | Dr. Satyaprasad Premswarup Senanayak | The Peridot Technologies | Non-Govt. | Physical Sciences | 2021 | 1.44 | 1 Years | (From NISER) |
| Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: prospective observational study | Dr. Sarbani Ghosh Laskar | IMRT-IGRT/ Rapidarc Inc Ltd (Madison, WI, USA) | Non-Govt. | Medical and Health Sciences | 2/1/2017 | 93.16 | 5 Years 6 Months | TMC |
| KINDLE- A multi-country, multi-centre, observational, retrospective study to reveal the patient characteristics, disease burden, treatment patterns and patient journey of stage III non-small-cell lung cancer patients | Dr. Kumar Prabhash | Astra Zeneca Non-Govt. India Ltd. | Non-Govt. | Medical and Health Sciences | 7/25/2019 | 7.46 | 2 Years | TMC |
| Max Plank Partner Group | Dr. Guneshwar Thangjam | Max Plank Partner Group | Non-Govt. | Physical Sciences | 2020 | 84.68 | 5 Years | (From NISER) |
| MK3475-593-03: A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) in India (Keynote-593) | Dr. Jyoti Bajpai | MSD ceuticals Pvt Ltd | Non-Govt. | Medical and Health Sciences | 6/30/2020 | 503.81 | 5 Years | TMC |
| MPI-IMSC PARTNER GROUP | PROF AREEJIT SAMAL | MAX PLANCK INSTITUTE | Non-Govt. | Life Sciences | 2018 | 31.89 | 5 YEARS | IMSc |
| Multi-Centric Clinical Trials of Indigenous TKP 2.4: Implant and Pilot Production of TKP 2.4 | Dr. Ashish Gulia | Non-ferrous Materials Technology Development Centre, Hyderabad | Non-Govt. | Medical and Health Sciences | 2/18/2019 | 427.90 | 5 Years | TMC |
| Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab compared with Chemotherapy in Patients with Treatment-Naïve Advanced or Recurrent (Stage IIIB not amenable for multimodality treatment) or Metastatic(Stage IV) Non-Small Cell Lung Cancer who are deemed unsuitable for Platinum-Containing therapy | Dr. Kumar Prabhash | Roche Products (India) Pvt. Ltd | Non-Govt. | Medical and Health Sciences | 11/23/2017 | 199.11 | 4 Years 4 Months | TMC |

Compilation of data as received from Dean-Academic of the various Cis/OCC of

Dr. P. S. Patil / Prof. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, जगज्ज्वलानगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Parents' Experiences with Prognosis Communication about their Children with Advanced Cancer | Dr. Anuja Damani | ALLANASONS PVT LTD | Non-Govt. | Medical and Health Sciences | 5/8/2019 | 10.00 | 3 Years | TMC |
| Phase 3 non inferiority randomised study between low dose immunotherapy and cytotoxic chemotherapy in 2nd line or beyond setting in relapsed-recurrent or metastatic solid tumors | Dr. Rajendra Badwe | Trilokchand Papiwal Charitable Trust | Non-Govt. | Medical and Health Sciences | 1/29/2020 | 331.29 | 5 Years | TMC |
| Phase IIb/III, Placebo-controlled, double-blind randomized clinical trial, using Curcumin and Metformin in patients with previous history of head and neck squamous cell carcinoma, in an attempt to lower the incidence of second primary tumor | Dr. Sudhir Vasudevan Nair | NATIONAL CANCER GRID | Non-Govt. | Medical and Health Sciences | 9/28/2018 | 30.79 | 6 Years | TMC |
| Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer | Dr. Rahul Krishnatry | NRG Oncology | Non-Govt. | Medical and Health Sciences | 10/10/2019 | 84.73 | 6 Years | TMC |
| Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer- CompARE trial | Dr. Devendra Chaukar | AstraZeneca/University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT | Non-Govt. | Medical and Health Sciences | 9/14/2020 | 58.86 | 6 Years | TMC |
| Phase III Randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy. | Dr. Supriya Chopra | NATIONAL RESEARCH GROUP (NRG) | Non-Govt. | Medical and Health Sciences | 2/22/2019 | 92.16 | 9 Years | TMC |
| Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer | Dr. Kumar Prabhash | ICON | Non-Govt. | Medical and Health Sciences | 11/2/2012 | 26.12 | 10 Years | TMC |
| Phase III trial of Observation versus Irradiation for a gross totally resected grade II Meningioma | Dr. Tejpal Gupta | NRG Oncology/RTOG | Non-Govt. | Medical and Health Sciences | 4/11/2019 | 12.30 | 12 Years | TMC |
| Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study | Dr. Bhausaheb Bagal | Amgen Inc | Non-Govt. | Medical and Health Sciences | 11/14/2019 | 122.98 | 4 Years 11 Months | TMC |

Compilation of data as received from Dean-Academic of the various Cis/OCC of HBNI.

MJN

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| PReCedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs) | Dr. Ameya Puranik | Terry Fox Foundation | Non-Govt. | Medical and Health Sciences | 7/10/2019 | 24.00 | 8 Years | TMC |
| Precision medicine and Malnutrition- A Model based approach to dose chemotherapy in pediatric patients with malnutrition | Dr. Girish Chinnaswamy | Terry Fox Foundation | Non-Govt. | Medical and Health Sciences | 5/8/2018 | 172.91 | 5 Years | TMC |
| Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes." | Dr. Jyoti Bajpai | Roche Pvt. Ltd | Non-Govt. | Medical and Health Sciences | 1/2/2017 | 13.88 | 6 Years | TMC |
| Prevalence of MMR status in gallbladder cancer (GBC) treated with palliative intent and its correlation with response to chemotherapy and survival. | Dr. Vikas Ostwal | Educational grant from Cadila healthcare limited | Non-Govt. | Medical and Health Sciences | 6/27/2018 | 15.28 | 4 Years | TMC |
| Prevalence of RAS and BRAF mutations in subjects diagnosed with Colorectal Cancer- a prospective, single center study | Dr. Prachi Patil | Merck Inc. unrestricted educational grant | Non-Govt. | Medical and Health Sciences | 8/2/2013 | 12.50 | 7 Years 5 Months | TMC |
| Profiling the incidence of ROS1 alteration discovered in human Non Small Cell Lung Cancer | Dr. Kumar Prabhsh | PFIZER PVT LTD | Non-Govt. | Medical and Health Sciences | 6/19/2017 | 42.59 | 3 Years | TMC |
| Prospective observational cohort study of advanced Gall bladder cancer patients to study the impact of clinical and molecular characteristics and outcome | Dr. Vikas Ostwal | MERCK PVT LTD | Non-Govt. | Medical and Health Sciences | 12/21/2015 | 39.66 | 7 Years | TMC |
| Prospective PeriOperative study Evaluating Routine Coagulation versus Thromboelastography for Liver resections (More Than Three Segments) (PORTAL Trial) | Dr. Reshma Ambulkar | TRAC | Non-Govt. | Medical and Health Sciences | 2/27/2020 | 1.23 | 1 Years | TMC |
| Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy. | Dr. Sudeep Gupta | Intas ceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India | Non-Govt. | Medical and Health Sciences | 9/27/2018 | 244.65 | 4 Years | TMC |

Compilation of data as received from Dean-Academic of the various CIS/OCC of HANI
 Dear Homi Bhabha National Institute
 प्रशासक, विद्यालय भवन, अणुशक्ति नगर, मुंबई
 प्रो. पी. डी. नाईक - Prof. P. D. Naik
 डॉ. होमी भाभा राष्ट्रीय संस्थान
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Response-Adapted Management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by Positron Emission and Computerized Tomography (PET-CT) to allow Omission of Radiotherapy in Indian Children Treated with a Standard of Care Intensified Chemotherapy Regimen | Dr. Badira Parambil | TRAC | Non-Govt. | Medical and Health Sciences | 8/5/2020 | 46.02 | 8 Years | TMC |
| Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence. | Dr. Sudeep Gupta | OncoStem Diagnostics, Bangalore | Non-Govt. | Medical and Health Sciences | 9/8/2014 | 14.66 | 7 Years 9 Days | TMC |
| Reverse swing-M : Repurposing of Mebendazole in recurrent glioblastoma. | Dr. Vijay Patil | Brain Tumor Foundation, ICON CRSF, ICMR | Non-Govt. | Medical and Health Sciences | 12/6/2017 | 47.98 | 5 Years | TMC |
| Role of toll-like receptors and TLR agonists in modulating response to chemotherapy in TNBC patients | Dr. Shalaka Joshi | Funding received from Department of Biotechnology, BioCare call for proposal in 2018 | Non-Govt. | Medical and Health Sciences | 1/20/2020 | 41.13 | 3 Years 3 Months | TMC |
| Safety Study of Nivolumab for Selected Advanced Malignancies in India | Dr. Kumar Prabhash | Bristol-Myers Squibb Research and Development | Non-Govt. | Medical and Health Sciences | 9/19/2017 | 107.82 | 3 Years | TMC |
| Salivary DNA as a diagnostic tool in Oral Cavity Squamous Cell Carcinoma (Salivary DNA Study) | Dr. Sudhir Vasudevan Nair | University of Chicago Trust in India, Bangalore | Non-Govt. | Medical and Health Sciences | 3/29/2019 | 11.10 | 2 Years 6 Months | TMC |
| Scalp Cooling for the prevention of chemotherapy induced alopecia in breast cancer from a tertiary care cancer center in India | Dr. Jyoti Bajpai | Access Devices | Non-Govt. | Medical and Health Sciences | 8/9/2016 | 5.77 | 8 Years | TMC |
| Study of hormonal receptors in low grade endometrial stromal sarcoma and correlation with clinical parameters | Dr. Santosh Menon | Surbhi Nag Foundation | Non-Govt. | Medical and Health Sciences | 8/27/2018 | 6.00 | 4 Years | TMC |
| The molecular landscape of diffuse large B-cell lymphomas on the Indian sub-continent | Dr. Manju Sengar | DUKE GLOBAL HEALTH INSTITUTE /DBT | Non-Govt. | Medical and Health Sciences | 5/31/2014 | 29.88 | 7 Years | TMC |

Compilation of data as received from Dean-Academic of the various **Cis/OCC** of HBNI.

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Total Marrow and Lymphoid Irradiation (TMLI) as conditioning regimen for peripheral stem cell transplant in high risk/ relapsed /refractory leukemias. | Dr. Jayant Goda | extramural: CSIR | Non-Govt. | Medical and Health Sciences | 10/24/2019 | 61.31 | 5 Years | TMC |
| Trastuzumab in HER2 positive Advanced Biliary tract cancers - single arm prospective phase II clinical trial (TAB trial) | Dr. Vikas Ostwal | Educational grant from Dr reddy's limited | Non-Govt. | Medical and Health Sciences | 10/28/2019 | 453.82 | 5 Years | TMC |
| Tumor Suppressors and Oncogenes: From Endometrial Cancer Cell Lines to Endometrial Cancer Tissues | Dr. Bharat Rekhi | NIRRH | Non-Govt. | Medical and Health Sciences | 4/24/2019 | 5.00 | 2 Years 10 Months | TMC |
| Use of PET-CT with Gallium-68 labelled prostate Specific Membrane Antigen in the Diagnosis and Follow-up of patients with Prostate Cancer | Dr. Archi Agrawal | IAEA | Non-Govt. | Medical and Health Sciences | 4/24/2018 | 16.22 | 4 Years | TMC |
| Utility of MRI in detecting peritoneal metastases in gastric cancer patients with negative CECT abdomen | Dr. Akshay Baheti | CIPLA | Non-Govt. | Medical and Health Sciences | 1/22/2018 | 6.80 | 4 Years | TMC |
| Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer - India | Dr. Deepa Nair | Case Western University, cleaveland | Non-Govt. | Medical and Health Sciences | 10/30/2018 | 9.02 | 3 Years 6 Months | TMC |
| Validation of the Tata MD CHECK CRISPR SARS-CoV-2 test 1.0 for the diagnosis of COVID-19 | Dr. Omshree Shetty | Tata Medical and Diagnostics Limited | Non-Govt. | Medical and Health Sciences | 1/27/2021 | 2.93 | 3 Months | TMC |
| Validation of the TataMD CHECK CRISPR SARS-CoV-2 test 1.0 for the diagnosis of COVID-19 | Dr. Omshree Shetty | Tata Medical and Diagnostics Limited | Non-Govt. | Medical and Health Sciences | 1/27/2021 | 2.93 | 3 Months | TMC |
| Validation Study Of The HURRIA Score In Predicting Chemotherapy Toxicity Risk In Elderly Population Undergoing Chemotherapy For Breast, Gastrointestinal And Gynecological Cancers In Indian Setup | Dr. Vikas Ostwal | INTAS CEUTICAL PVT LTD | Non-Govt. | Medical and Health Sciences | 8/9/2016 | 14.85 | 5 Years | TMC |

Compilation of data as received from Dean - Academic of the various CIs/OCC of HBNI

Dr. P. D. Gaik
 डॉ. पी. डी. गायक
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Protocol No. EMR 062202 559- A prospective, open label, multicentric data collection registry in order to describe treatment choices in management of metastatic colorectal cancer (mCRC) patients with unresectable hepatic and / or extra hepatic disease, across treatment lines (Asian Metastatic Colorectal Cancer Registry) | Dr. Shailesh Shrikhande | Merck PVT Ltd. | Non-Govt. | Medical and Health Sciences | 9/23/2013 | 8.90 | 9 Years | TMC |
| Protocol no. NOPRODPCR4001- A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia | Dr. Amit Joshi | Janssen Asia Pacific Medical Affairs | Non-Govt. | Medical and Health Sciences | 9/21/2016 | 38.23 | 5 Years | TMC |
| Protocol No. RI-02-003- Reditux TM Registry to compare Effectiveness, Safety and Resource Utilization of Reditux vs. the Reference Medicinal Product to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia in Routine Clinical Practice | Dr. Manju Sengar | DR.REDDYS LAB/Phamax Analytic Resources Pvt Ltd | Non-Govt. | Medical and Health Sciences | 2/22/2016 | 32.64 | 6 Years | TMC |
| Protocol Number: CO41101 A Phase III, Double Blind, Placebo-Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer. | Dr. Sudeep Gupta | F. Hoffmann-La Roche Ltd | Non-Govt. | Medical and Health Sciences | 9/21/2020 | 476.18 | 6 Years | TMC |
| Protocol Number: CO41101 A Phase III, Double Blind, Placebo-Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer. | Dr. Sudeep Gupta | F. Hoffmann-La Roche Ltd | Non-Govt. | Medical and Health Sciences | 9/21/2020 | 476.18 | 6 Years | TMC |
| Quality Assurance (QA) Program for Molecular Diagnostic testing in Solid Tumors | Dr. Omshree Shetty | NCG | Non-Govt. | Medical and Health Sciences | 12/8/2017 | 111.06 | 5 Years | TMC |
| RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA | Dr. Reena Engineer | Extramural RTOG | Non-Govt. | Medical and Health Sciences | 6/8/2020 | 275.22 | 5 Years | TMC |
| Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in hepatocellular carcinoma (IAEA study) | Dr. Supriya Chopra | IAEA | Non-Govt. | Medical and Health Sciences | 11/22/2016 | 9.40 | 6 Years | TMC |
| Response-Adapted Management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by Positron Emission and Computerized Tomography (PET-CT) to allow Omission of Radiotherapy in Indian Children Treated with a Standard of Care Intensified Chemotherapy Regimen | Dr. Badira Parambil | TRAC | Non-Govt. | Medical and Health Sciences | 8/5/2020 | 46.02 | 8 Years | TMC |

Compilation of data as received from Dean - Academic of ~~the various~~ various Cis/OCC of ~~the various~~ HBNI.

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, | Dr. Jyoti Bajpai | Eli Lilly and Company India Pvt. Ltd | Non-Govt. | Medical and Health Sciences | 11/30/2016 | 116.30 | 6 Years | TMC |
| Protocol No. - LUF-44-001 : Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study | Dr. Suyash Kulkarni | Guerbet | Non-Govt. | Medical and Health Sciences | 2/27/2020 | 1.81 | 1 Years | TMC |
| Protocol No. - NEO - ALTTO - CLAP016B2302 : A randomized, multicenter, open-label, phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer. | Dr. Sudeep Gupta | GlaxoSmithKline Non-Govt.ceuticals Limited | Non-Govt. | Medical and Health Sciences | 5/18/2009 | 27.02 | 13 Years | TMC |
| Protocol No. - NIS/2018/19 : An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India | Dr. Sudeep Gupta | Glenmark Non-Govt.ceuticals Ltd. | Non-Govt. | Medical and Health Sciences | 6/15/2020 | 10.41 | 2 Years | TMC |
| Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03 | Dr. Sushmita Rath | Tanvex Biologics Corp. | Non-Govt. | Medical and Health Sciences | 10/9/2020 | 116.24 | 2 Years | TMC |
| Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05- | Dr. Sushmita Rath | Tanvex Biologics Corp. | Non-Govt. | Medical and Health Sciences | 10/9/2020 | 116.24 | 2 Years | TMC |
| Protocol No. CABAZL06500- A phase II controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel in recurrent head and neck cancer in India | Dr. Kumar Prabhash | SANOFI | Non-Govt. | Medical and Health Sciences | 1/29/2015 | 71.75 | 7 Years | TMC |
| Protocol no. CR201-18 A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- Controlled, Two Part, Phase III, Global Study to Evaluate the Non-Govt.cokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC). | Dr. Sushmita Rath | CuraTeQ Biologics GmbH c/o Moore Stepehns Luzern AG, Obergrundstrasse 61, 6003 Luzern. | Non-Govt. | Medical and Health Sciences | 1/27/2021 | 514.88 | 4 Years | TMC |
| Protocol no. CR201-18 A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- Controlled, Two Part, Phase III, Global Study to Evaluate the Non-Govt.cokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC). | Dr. Sushmita Rath | CuraTeQ Biologics GmbH c/o Moore Stepehns Luzern AG, Obergrundstrasse 61, 6003 Luzern. | Non-Govt. | Medical and Health Sciences | 1/27/2021 | 514.88 | 4 Years | TMC |

Compilation of data as received from Dean - Academic of the various CIS/OCC of HBNI.

प्रो. पी. डी. नाईक / Prof. P. D. Naik
 डॉ. होमी भाभा राष्ट्रीय संस्थान
 शिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Protocol No. - D9100C00001 : A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) | Dr. Sudeep Gupta | AstraZeneca Non-Govt. India limited. | Non-Govt. | Medical and Health Sciences | 2/25/2020 | 389.15 | 4 Years | TMC |
| Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) | Dr. Vikas Ostwal | Astra Zeneca Non-Govt. India Ltd. | Non-Govt. | Medical and Health Sciences | 10/5/2020 | 118.59 | 2 Years | TMC |
| Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) | Dr. Vikas Ostwal | AstraZeneca Non-Govt. India Ltd. | Non-Govt. | Medical and Health Sciences | 10/5/2020 | 118.59 | 2 Years | TMC |
| Protocol No. - DRL-INDG02-PAN/2018 : An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize its Safety, Tolerability and Activity in Indian Subjects with Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer | Dr. Vikas Ostwal | Dr. Reddy's Laboratories Ltd. | Non-Govt. | Medical and Health Sciences | 5/13/2020 | 26.89 | 2 Years | TMC |
| Protocol No. - E7080-M091-507 : Prospective Single Arm Post Marketing Phase IV study to assess the Safety and Efficacy of Lenvatinib in Subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer | Dr. Vijay Patil | Eisai Non-Govt.ceuticals India Pvt. Ltd. | Non-Govt. | Medical and Health Sciences | 10/31/2019 | 30.19 | 3 Years 1 Months | TMC |
| Protocol No. - ECTS/16/002 : A multicentric open label phase II safety and efficacy study of ormeloxifene in tamoxifen resistant metastatic/recurrent breast cancer patients. | Dr. Sudeep Gupta | HLL Lifecare Limited (A Government of India Enterprises) | Non-Govt. | Medical and Health Sciences | 10/8/2018 | 49.70 | 4 Years | TMC |
| Protocol No. - EGC002 : A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer | Dr. Sudeep Gupta | Eirgenix Inc. | Non-Govt. | Medical and Health Sciences | 7/1/2019 | 264.00 | 4 Years | TMC |
| Protocol No. - EIL-E7389-CT01-012 : Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Breast Cancer. | Dr. Sudeep Gupta | Eisai Non-Govt.ceuticals India Private Limited | Non-Govt. | Medical and Health Sciences | 8/16/2018 | 111.54 | 3 Years | TMC |

Compilation of data as received from Dean - Academic of the various Prof. P. C. N. S. / OCC of
 डॉ. पी. सी. न. एस. / डीन, होमी भाभा राष्ट्रीय संस्थान
 Dean, Homi Bhabha National Institute
 प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
 Training School Complex, Anushaktinagar, Mumbai - 400 094

HBNL

| Name of the Scheme/Project/ Endowments/ Chairs | Name of the Principal Investigator/ Co Investigator (if applicable) | Name of the Funding agency | Type (Govt./Non-Govt.) | Department | Year of Award | Funds provided (INR in lakhs) | Duration of the project | Cis/OCC |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------|---------------|-------------------------------|-------------------------|---------|
| Protocol No. - ALK18/ENZ124-CET1 : A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). | Dr. Kumar Prabhash | ALKEM LABORATORIES LIMITED | Non-Govt. | Medical and Health Sciences | 10/18/2019 | 146.84 | 2 Years 10 Months | TMC |
| Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer. | Dr. Vikas Ostwal | Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai â€ 400013, Maharashtra , Enzene Biosciences Limited, Plot Number | Non-Govt. | Medical and Health Sciences | 3/12/2021 | 13.18 | 1 Years 4 Months | TMC |
| Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer. | Dr. Vikas Ostwal | Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai â€ 400013, Maharashtra , Enzene Biosciences Limited, Plot Number | Non-Govt. | Medical and Health Sciences | 3/12/2021 | 13.18 | 1 Years 4 Months | TMC |
| Protocol No. - CBYL719C2301 : A phase III randomized double-blind, placebo controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment | Dr. Sudeep Gupta | Novartis Healthcare Private Limited | Non-Govt. | Medical and Health Sciences | 7/21/2016 | 94.95 | 5 Years | TMC |
| Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC). | Dr. Sudeep Gupta | Astra Zeneca Non-Govt. India Limited | Non-Govt. | Medical and Health Sciences | 10/12/2020 | 545.53 | 2 Years 4 Months | TMC |
| Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC). | Dr. Sudeep Gupta | AstraZeneca Non-Govt. India Limited | Non-Govt. | Medical and Health Sciences | 10/12/2020 | 545.53 | 2 Years 4 Months | TMC |
| Protocol No. - D5161C00005 : A prospective, multicenter, Phase-IV clinical trial to assess safety of TAGRISSOTM (Osimertinib) in Indian adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive nonsmall cell lung cancer (NSCLC). | Dr. Vanita Noronha | AstraZeneca Non-Govt. India Limited | Non-Govt. | Medical and Health Sciences | 1/21/2019 | 12.49 | 2 Years | TMC |

Compilation of data as received from *Dr. P. D. Wankar* Dean, Homi Bhabha National Institute of the various CIs/OCC of HSNIE

प्रो. पी. डी. वंकर
डॉ. होमी भाभा राष्ट्रीय संस्थान
Dean, Homi Bhabha National Institute
प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
Training School Complex, Anushaktinagar, Mumbai - 400 094

डॉ. होमी भाभा राष्ट्रीय संस्थान
Dean, Homi Bhabha National Institute
प्रशिक्षण विद्यालय भवन, अणुशक्तीनगर, मुंबई - 400 094
Training School Complex, Anushaktinagar, Mumbai - 400 094